MFN Goes Mid-Market: Nine More Drugmakers Sign Medicaid Pricing Deals as the September 29 Tariff Deadline Approaches
On August 31, 2026, the White House announced most-favored-nation (“MFN”) pricing agreements with nine additional pharmaceutical manufacturers: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements bring the total number of manufacturers with MFN deals to 26, which the White House says covers 89 percent of the branded drug market.